ArticleJournal of clinical laboratory analysis2026
Mesenchymal Stem Cell-Mediated Vascular Regeneration in Diabetic Foot Ulcers via the Notch Signaling Pathway.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveDiabetic Foot Ulcers (DFUs) represent a prevalent and serious complication of diabetes, frequently resulting in persistent wounds and delayed healing. This research explores the healing effects of mesenchymal stem cells (MSCs) on DFUs and examines the involvement of Notch signaling in this therapeutic process.
methodsBALB/c mice were induced with diabetes using streptozotocin (STZ) and divided into five groups: Control, Model, MSCs Treatment, MSCs + Notch Inhibition, and MSCs + Notch Activation. Wound healing was monitored, and tissue samples were analyzed using histological and molecular techniques.
resultsOur results demonstrated that MSCs treatment significantly accelerated wound healing, as evidenced by improved histopathology and enhanced expression of CD31, VEGF, FGF, and PECAM-1 in MSCs-treated groups. Notch activation further enhanced MSCs-mediated healing, as shown by increased Notch1 and Jagged-1 protein levels. Conversely, the MSCs + Notch Inhibition Group showed reduced healing and similar results to the Model Group, with lower expression of Notch1 and Jagged-1.
conclusionThese findings suggest that MSCs promote DFU healing, and Notch signaling plays a crucial role in enhancing MSC-mediated repair. Our results highlight the potential of MSC-based therapies combined with Notch pathway modulation as a promising strategy for improving DFU treatment and wound healing in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.